Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|February 4, 2022

Disorders and COVID-19

Michael J Thorpy, M.B., Ch.B and Karl Doghramji, MD discuss the impact of COVID-19 on sleep disorders and depression.

Episodes in this series

EP. 1 Overview and Incidence of Insomnia Disorder

EP. 1 Overview and Incidence of Insomnia Disorder

EP. 2 DSM-V Diagnostic Criteria for Sleep Disorders

EP. 2 DSM-V Diagnostic Criteria for Sleep Disorders

EP. 3 Overview of Parasomnias

EP. 3 Overview of Parasomnias

EP. 4 Treatments for Parasomnia and Sleep Disorders

EP. 4 Treatments for Parasomnia and Sleep Disorders

EP. 5 Disorders and COVID-19

EP. 5 Disorders and COVID-19

EP. 6 Insomnia: Treatment and Management Considerations

EP. 6 Insomnia: Treatment and Management Considerations

EP. 7 Insomnia Clinical Practice Pearls

EP. 7 Insomnia Clinical Practice Pearls

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

Brain Function Biomarker Testing In Psychiatry With Universal Brain EEG

ByKazu Okuda, MD

August 21st 2026

neuropsychiatry

Neuropsychiatry in the News: Wearable Technology for Parkinson Disease, Ecopipam for Tourette Syndrome

August 19th 2026

gguy/Adobe Stock

FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease

ByJessica Walters

August 14th 2026

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder

ByGerald A. Maguire, MD

August 11th 2026

stuttering

Psychiatry and the Treatment of Stuttering: A Blossoming Partnership

ByMike Hennessy Jr

August 11th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Trending on Psychiatric Times

Kratom Component in Clinical Trial for Opioid Use Disorder

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder